LivaNova PLC (LIVN) Cash Flow Statement

The OCF/NI ratio swung from 2.67 in 2025Q4 to 0.61 in 2026Q2, indicating that net income is increasingly decoupled from cash generation. This divergence appears driven by working capital outflows of $18.2M and a surge in receivables, which may signal aggressive revenue recognition or timing issues. Investors should monitor whether this gap narrows in subsequent quarters, as sustained low conversion could imply earnings are not fully backed by cash.

The sequential recovery in FCF from $0.9M to $35.0M aligns with the revenue acceleration and operating leverage noted in the income statement. However, FCF margins remain volatile, swinging from 21.2% in 2024Q4 to 4.2% in 2025Q1, indicating that cash generation is sensitive to working capital swings and one-time items. The raised full-year guidance suggests management expects sustained improvement, but the historical volatility warrants caution.

The elevated capex/revenue ratio suggests management is investing in capacity and product development to support the accelerating core business, particularly in Cardiopulmonary and Neuromodulation. While this may pressure near-term FCF, it appears aligned with the strategic focus on high-growth segments. The consistency of capex around 3-9% of revenue indicates a balanced approach between maintenance and growth spending, though the recent uptick warrants monitoring for returns.

The massive working capital inflow in 2025Q1 likely reflects a one-time settlement or collection, while the subsequent outflows suggest normalization. In 2026Q2, the $18.2M outflow indicates continued investment in receivables or inventory, possibly tied to revenue growth. This volatility masks underlying operational cash generation, and investors should adjust for these swings to assess true cash flow performance.

The absence of dividends and minimal buybacks suggests a deliberate strategy to conserve cash for R&D and potential acquisitions, consistent with the company's investment in clinical trials and supply chain security. This approach may appeal to growth-oriented investors but could disappoint income-focused shareholders. The recent Thermo Fisher agreement underscores the focus on operational resilience rather than capital return.

The large divergence is primarily due to the $327.3M net loss in 2025Q1, likely from litigation charges, while operating cash flow remained positive. This suggests that the company's core operations are cash-generative, and the accounting losses are non-cash or one-time in nature. However, the cumulative OCF/NI ratio of -77.5x is distorted by the loss, and investors should focus on the underlying cash flow stability, which appears robust.